Respire Diagnostics (REDI)

Our Next Generation ReDi (“Respire Diagnostics”) medical devices use exhaled breath to identify biomarkers that correlate to diseases for patient identification and condition monitoring. We are currently conducting our clinical trials and regulatory approvals. Our REDI device aim to use biomarkers like Hydrogen Peroxide (H2O2), lactate and nitrites, which acts as a proxy for common respiratory diseases (COPD, asthma), sepsis, and the fitness market. Respire Diagnostics is a spin-out from Imperial College London. We were recruited by the UK Department for International Trade to set up our HQ in London, receiving funding from the UK Research and Innovation's Innovate UK, Medtech SuperConnector and EIT Health. Respire Diagnostics completed Tech Transfer at Imperial College of London (TRL4), and conducted two clinical studies with Royal Brompton and Harefield Hospital (National Heart and Lung Institute) (TRL5). We are now working towards acquiring Regulatory Approval (ISO13485) for our REDI medical devices. We aim to expand our sensor portfolio of potential biomarkers to target other diseases.